Amr Radwan | Immunology | Best Researcher Award

Posted on by sciencefather

Dr. Amr Radwan | Immunology | Best Researcher Award

Executive Medical Director at Regeneron, United Kingdom

Dr. Amr AH Radwan is a distinguished medical affairs leader with over two decades of global experience spanning clinical medicine, pharmaceutical medicine, immunology, gastroenterology, and strategic leadership in drug development and market access. Currently serving as Executive Medical Director at Regeneron Pharmaceuticals Inc., he brings deep scientific expertise and cross-functional insight to global medical affairs, particularly in immunological disorders and biologics. His work bridges the interface of clinical innovation, medical strategy, regulatory frameworks, and international healthcare markets.

Publication Profile 

Orcid

Educational Background 🎓

  • University of Cambridge

    • MB BChir (Bachelor of Medicine and Surgery), 1998

    • BA in Pathology (Honours), 1996

    • MA (Cantab), 1999

  • Royal College of Surgeons (Edinburgh)

    • AFRCS Part 1 (MCQ I & II), 2001

  • The Berne Institute, Kegworth

    • Foundation Training in Transactional Analysis Counselling & Psychotherapy, 2003

  • University of Cardiff

    • Diploma in Pharmaceutical Medicine, 2010

  • Royal College of Physicians

    • Membership of Faculty of Pharmaceutical Medicine, 2011

    • Specialist Training in Pharmaceutical Medicine, 2011

    • Fellowship, 2016

Professional Experience 💼

🏢 Regeneron Pharmaceuticals Inc. (2018–Present)

  • Executive Medical Director, Global Medical Affairs (2022–Present)

  • Senior Director, Global Medical Affairs (2019–2021)

  • Senior Director, Medical Affairs EU (2018–2019)

    • Key leadership in global immunology franchise across dermatology, respiratory, and GI indications (e.g., Dupilumab, Itepekimab).

    • Led GI franchise (EoE, EoG, eUC) strategy and ex-US medical organization restructuring.

    • Partnered with commercial, legal, and R&D teams for European, Canadian, and Japanese market expansions.

🏢 Aimmune Therapeutics Ltd. (2016–2018)

  • Vice President, Medical Affairs & Market Access

    • EU and global leadership for peanut allergy therapy; directed Drug Safety & PV, Market Access, and clinical trial governance.

🏢 Norgine Pharmaceuticals UK Ltd. (2014–2016)

  • Medical Director – EU

    • Led EU medical affairs, market access, PV, and NICE submission strategies; managed 8 country-level medical teams; oversaw clinical trials and licensing responses.

Research Interests 🔬

  • Pharmaceutical Medicine & Clinical Drug Development

  • Immunology, Dermatology, and Gastroenterology (e.g., EoE, PN, CRSwNP)

  • Allergic Disorders and Biologics (e.g., anti-IL33, anti-Fel D1)

  • Regulatory Compliance, Pharmacovigilance & Risk Management

  • Clinical Strategy and Market Access Studies

Awards and Honors🏆✨

  • Queens’ College Exhibition Prize (1994–1996)
    Awarded for First Class academic performance in Preclinical Sciences.

  • Fawcett Memorial Prize (1998)
    Recognized for Outstanding Communication Skills.

  • Fellowship of the Faculty of Pharmaceutical Medicine (2016)
    Awarded by Royal College of Physicians for significant contributions to Pharmaceutical Medicine.

Additional Credentials & Interests

  • Languages & Communication: Fluent in Arabic, English, and French.

  • Advanced Certifications:

    • IAM-trained motorcyclist (Institute of Advanced Motorists)

    • PADI Advanced & BSAC Sports Scuba Diving certifications

  • Hobbies:

    • Partner dancing (Argentine Tango, Blues, Modern Jive)

    • Literature, philosophy, and motorcycling

Conclusion🌟

Dr. Amr AH Radwan is a highly accomplished physician-leader whose contributions have shaped global medical affairs practices, especially in immunology and allergy-based therapeutics. His unique blend of clinical training, regulatory expertise, and cross-continental leadership makes him a significant figure in modern pharmaceutical medicine and translational healthcare strategy. He is well-suited for high-level recognition, awards, and continued leadership in both academic and industry circles.

Publications 📚

  1. 📄 A Real-World Study of Cumulative Steroid Burden Among Patients with Eosinophilic Esophagitis in the United States
    📰 Clinical Gastroenterology and Hepatology (Mar 2025)
    🔗 DOI: 10.1016/j.cgh.2025.01.010

  1. 📄 Baseline Disease Characteristics by Surgery History Among Patients with CRSwNP: AROMA Registry
    📰 American Journal of Otolaryngology (Mar 2025)
    🔗 DOI: 10.1016/j.amjoto.2024.104596

  1. 📄 Dupilumab Efficacy and Safety in Children With Moderate to Severe Asthma and High Blood Eosinophils: VOYAGE (Post Hoc)
    📰 The Journal of Allergy and Clinical Immunology: In Practice (Mar 2025)
    🔗 DOI: 10.1016/j.jaip.2024.11.014

  1. 📄 Burden of Eosinophilic Esophagitis in Adults and Adolescents: Real-World Analysis
    📰 Diseases of the Esophagus (Mar 3, 2025)
    🔗 DOI: 10.1093/dote/doaf024

  1. 📄 Dupilumab Efficacy in EoE Irrespective of Prior Swallowed Corticosteroids: LIBERTY EoE TREET Trial
    📰 Expert Review of Gastroenterology & Hepatology (Feb 2025)
    🔗 DOI: 10.1080/17474124.2025.2461516

  1. 📄 Current Smoker: A Clinical COPD Phenotype Affecting Disease Progression and Therapy Response
    📰 American Journal of Respiratory and Critical Care Medicine (Feb 12, 2025)
    🔗 DOI: 10.1164/rccm.202407-1379ci

  1. 📄 Dupilumab Induces Long-Term On-Treatment Clinical Remission in Type 2 Asthma
    📰 The Journal of Allergy and Clinical Immunology: In Practice (Jan 2025)
    🔗 DOI: 10.1016/j.jaip.2024.10.009

  1. 📄 Disease Burden and Symptoms Impacting Quality of Life in Pediatric EoE Patients
    📰 Gastro Hep Advances (2024)
    🔗 DOI: 10.1016/j.gastha.2024.08.009

  1. 📄 Real-World Characteristics of Severe Asthma Patients Before Dupilumab: ProVENT Study
    📰 Respiration (2024)
    🔗 DOI: 10.1159/000535390

  1. 📄 Dupilumab Efficacy in Children With Type 2 Asthma on High-/Medium-Dose ICS (VOYAGE)
    📰 The Journal of Allergy and Clinical Immunology: In Practice (Dec 2024)
    🔗 DOI: 10.1016/j.jaip.2024.08.038

 

 

 

 

 

Prabhjyoti Pahwa | Immunology | Best Researcher Award

Posted on by sciencefather

Ms. Prabhjyoti Pahwa | Immunology | Best Researcher Award

Ph.D. Student at Institute of Liver and Biliary Sciences, India

Prabhjyoti Pahwa is a dedicated Ph.D. scholar at the Institute of Liver and Biliary Sciences, New Delhi, with a focus on immunology and liver diseases. Her work spans a wide range of research areas, from viral infections to immune-metabolic responses in liver disease pathogenesis. She has actively contributed to multiple peer-reviewed publications in leading journals, particularly exploring immune alterations in diseases like Hepatitis E and B, as well as in COVID-19 during pregnancy. As a researcher, she combines a strong technical skillset in molecular biology and cell biology with a passion for understanding the immune system’s role in liver diseases. Prabhjyoti is committed to advancing the field of hepatology through innovative research, with a vision to improve maternal and fetal health outcomes in viral infections.

Publication Profile : 

Scopus

Educational Background 🎓

  • Ph.D. (2022 – Present)
    Institute of Liver and Biliary Sciences, New Delhi
  • Junior Research Fellow (2020 – 2022)
    Institute of Liver and Biliary Sciences, New Delhi
  • M.Sc. in Biotechnology (2017 – 2019)
    Panjab University, Chandigarh
    GPA: 3.45 (86.24%)
  • B.Sc. in Zoology (Hons.) (2014 – 2017)
    Zakir Husain Delhi College, University of Delhi
    GPA: 3.199 (79.99%)
  • Intermediate (Class 12, 2014)
    RPVV Raj Niwas Marg, Delhi
    80.04%
  • Matriculation (Class 10, 2012)
    B.M. Ganges Girls’ Senior Secondary School, Delhi
    CGPA: 8.2

Professional Experience 💼

Prabhjyoti Pahwa is currently a Junior Research Fellow and Ph.D. Scholar at the Institute of Liver and Biliary Sciences (ILBS), New Delhi, where she has been conducting cutting-edge research on hepatology and immunology since 2020. Her research focuses on Hepatitis E Virus (HEV) infection during pregnancy and its severe maternal and fetal outcomes, as well as the immune-metabolic shifts in various liver diseases, including Hepatitis B and C. Throughout her research career, she has worked under the mentorship of Prof. Nirupama Trehanpati and collaborated with prominent researchers in the field of liver diseases. Previously, she was a Master’s student at Panjab University, Chandigarh, where she gained practical experience in biotechnology, cell biology, and molecular techniques. She has also worked on several collaborative projects, contributing to a diverse range of research topics, from lipase-producing bacteria to biosensors for pesticide detection.

Research Interests 🔬

Prabhjyoti’s primary research interests include:

  • Hepatitis E virus (HEV) and its impact during pregnancy
  • Immuno-metabolic shifts in liver diseases, especially in pregnant women with viral infections
  • The role of T cells, natural killer cells, and cytokines in the progression of liver diseases like hepatitis B
  • Single-cell RNA sequencing for exploring immune responses in chronic viral infections
  • Investigating metabolomic alterations and their correlation with disease severity in liver diseases and SARS-CoV-2 infections during pregnancy.

Publications 📚

  1. Prabhjyoti Pahwa, Deepti Sharma*, Pushpa Yadav, Sherin Sarah Thomas, Sandhya Hora, Preedia Babu E., Gayatri Ramakrishna, Shiv Kumar Sarin*, Nirupama Trehanpati*.
    Prognostic role of serum VEGF and HGF post SBRT in advanced hepatocellular carcinoma.
    Journal of Clinical and Experimental Hepatology, 2024 (Accepted in October 2024).

  2. Anoushka Saxena, Minal, Prabhjyoti Pahwa, Jaswinder Singh Maras, Hamda Siddiqui, Jayesh Kumar Sevak, Y.M. Mala, Shakun Tyagi, Shiv Kumar Sarin, Nirupama Trehanpati.
    Immuno-metabolic shifts in acute liver failure caused by hepatitis E virus infection during pregnancy and their association with obstetric outcomes.
    Hepatology Communication, 2024 (Accepted in October 2024).

  3. Prabhjyoti Pahwa, Ashish Kumar Vyas, Jayesh Kumar Sevak, Ravinder Singh, Jaswinder Singh Maras, Sharda Patra, Shiv K Sarin, Nirupama Trehanpati*.
    Modulation of CD8+ T cells, natural killer cells and Th1 cytokines by metabolic milieu in decline of HBV viremia in pregnant women treated with Tenofovir disoproxil from second trimester of pregnancy.
    Journal of Reproductive Immunology, 2024, Volume 162.

  4. Sandhya Hora$, Prabhjyoti Pahwa$, Hamda Siddiqui, Anoushka Saxena, Minal Kashyap, Jayesh Kumar Sevak, Ravinder Singh, Maryam Javed, Pushpa Yadav, Pratibha Kale, Gayatri Ramakrishna, Meenu Bajpai, Asmita Rathore, Jaswinder Singh Maras, Shakun Tyagi*, Shiv Kumar Sarin*, Nirupama Trehanpati*.
    Metabolic alterations unravel the materno–fetal immune responses with disease severity in pregnant women infected with SARS-CoV-2.
    Journal of Medical Virology, December 2023, Volume 95, Issue 12.
    DOI: 10.1002/jmv.29257.

  5. Prabhjyoti Pahwa1, Ravinder Singh1, Partha Chattopadhyay2, Priyanka Mehta2, Sharda Patra3, Rajesh Pandey2, Shakun Tyagi4, Shiv Kumar Sarin5*, Nirupama Trehanpati1*.
    Single cell RNA sequencing reveals exhausted adaptive immunity in utero to HBV exposed neonates born to mothers with high HBsAg titres persisting despite vaccination.
    Hepatology, AASLD 2024, Poster of Distinction.

  6. Prabhjyoti Pahwa, Fatima Ali, Ashish Kumar Vyas, Sharda Patra, Shiv K Sarin, Nirupama Trehanpati*.
    Decline in viral load induces CD8+ T cells, natural killer cells and Th1 cytokine profile in chronic hepatitis B infected pregnant women treated with Tenofovir disoproxil from second trimester.
    Oral Presentation, AASLD 2022.

  7. Anoushka Saxena, Hamda Siddiqui, Jayesh Kumar Sevak, Minal, Prabhjyoti Pahwa, Fatima Ali, Shakun Tyagi, Shiv Kumar Sarin, Nirupama Trehanpati*.
    IL-7 induced CD4+ Memory stem T cell-derived pro-inflammatory cytokine storm plays a role in hepatitis E induced pathogenesis in pregnant women.
    AASLD 2022.

  8. Anoushka Saxena, Minal Kashyap, Prabhjyoti Pahwa, Fatima Ali, Hamda Siddiqui, Preedia Babu E., Y.M. Mala, Shakun Tyagi, Nirupama Trehanpati.
    Elevated serum bilirubin levels and aminotransferases are associated with immuno-modulatory and suppressive subsets in pregnant females with intrahepatic cholestasis and hepatitis E virus infection.
    EASL 2022.

  9. Anoushka Saxena, Prabhjyoti Pahwa, Hamda Siddiqui, Jaswinder Singh Maras, Rashi Sehgal, Sharda Patra, Shiv Kumar Sarin, Nirupama Trehanpati.
    The metabolome profiling of patients infected with hepatitis E virus unravels the role of Nicotinate and Nicotinamide pathway and D-glutamine and glutamate metabolism in the development of Acute Liver Failure.
    AASLD 2021.

  10. Prabhjyoti Pahwa, Hamda Siddiqui, Fatima Ali, Jayesh Kumar Sevak, Archana Rastogi, Sakshi Aggarwal, Shakun Tyagi, Nirupama Trehanpati, Asmita Rathore.
    Rise in pro- and anti-inflammatory cytokines in asymptomatic and mild COVID-19 pregnant patients than moderate to severe patients.
    AOGD 2021.